Cargando…
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278456/ https://www.ncbi.nlm.nih.gov/pubmed/30365076 http://dx.doi.org/10.3892/or.2018.6802 |
| _version_ | 1783378370384363520 |
|---|---|
| author | Lubet, Ronald A. Steele, Vernon E. Juliana, M.M. Bode, Ann Moeinpour, Fariba Grubbs, Clinton J. |
| author_facet | Lubet, Ronald A. Steele, Vernon E. Juliana, M.M. Bode, Ann Moeinpour, Fariba Grubbs, Clinton J. |
| author_sort | Lubet, Ronald A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6278456 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | D.A. Spandidos |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-62784562018-12-17 Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models Lubet, Ronald A. Steele, Vernon E. Juliana, M.M. Bode, Ann Moeinpour, Fariba Grubbs, Clinton J. Oncol Rep Corrigendum D.A. Spandidos 2019-01 2018-10-17 /pmc/articles/PMC6278456/ /pubmed/30365076 http://dx.doi.org/10.3892/or.2018.6802 Text en Copyright: © Lubet et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| spellingShingle | Corrigendum Lubet, Ronald A. Steele, Vernon E. Juliana, M.M. Bode, Ann Moeinpour, Fariba Grubbs, Clinton J. Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models |
| title | Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models |
| title_full | Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models |
| title_fullStr | Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models |
| title_full_unstemmed | Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models |
| title_short | Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models |
| title_sort | daily or weekly dosing with egfr inhibitors, gefitinib and lapatinib, and akt inhibitor mk2206 in mammary cancer models |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278456/ https://www.ncbi.nlm.nih.gov/pubmed/30365076 http://dx.doi.org/10.3892/or.2018.6802 |
| work_keys_str_mv | AT lubetronalda dailyorweeklydosingwithegfrinhibitorsgefitinibandlapatinibandaktinhibitormk2206inmammarycancermodels AT steelevernone dailyorweeklydosingwithegfrinhibitorsgefitinibandlapatinibandaktinhibitormk2206inmammarycancermodels AT julianamm dailyorweeklydosingwithegfrinhibitorsgefitinibandlapatinibandaktinhibitormk2206inmammarycancermodels AT bodeann dailyorweeklydosingwithegfrinhibitorsgefitinibandlapatinibandaktinhibitormk2206inmammarycancermodels AT moeinpourfariba dailyorweeklydosingwithegfrinhibitorsgefitinibandlapatinibandaktinhibitormk2206inmammarycancermodels AT grubbsclintonj dailyorweeklydosingwithegfrinhibitorsgefitinibandlapatinibandaktinhibitormk2206inmammarycancermodels |